Hunt said he at first suffered side effects, including vomiting, diarrhea, stomach pains, weight loss and constipation. But by lowering his dosage, the side effects eventually diminished, he said. Dose reduction was required in 79 percent of clinical trial patients, according to the FDA.
Hunt receives monthly doses of the drug along with tests for calcitonin, as well as quarterly scans for tumors.
Between doses, he and his wife Nancy, a retired schoolteacher, travel extensively, including trips in the past year to California, Texas, Missouri and Australia.
"We're still active, so that's a good thing," said Hunt, noting that the couple, who have lived 47 years in Phoenix, still go regularly to the gym and are active in their church.
"I'm excited. I played a part in making it (FDA approval) happen," Hunt said. "I thank God that I was chosen to take part in obtaining the approval of the medication. If it works for me, it's going to work for other people, and that's good."
In addition to treating MTC, cabozantinib is being explored as a therapy for numerous tumor types, including prostate, ovarian, brain, melanoma, breast, and non-small cell lung cancers.
|Contact: Steve Yozwiak|
The Translational Genomics Research Institute